Remeditex Ventures, a US-based venture capital (VC) firm set up by former executives at Hunt Petroleum and technology transfer professionals at Texas University's UT Southwestern Medical Center, led MiRagen's round, and was joined by peers Atlas Venture, Boulder Ventures and Broadview Ventures, as well as Amgen.

MiRagen Therapeutics, a US-based biopharmaceutical firm to treat muscle disease, has raised $20m in its series B round from a consortium including Amgen Ventures, the corporate venturing division of biotechnology corporation Amgen.

Remeditex Ventures, a US-based venture capital (VC) firm set up by former executives at Hunt Petroleum and technology transfer professionals at Texas University’s UT Southwestern Medical Center, led MiRagen’s round, and was joined by peers Atlas Venture, Boulder Ventures and Broadview Ventures, as well as Amgen.

Miragen…